PRINCETON, N.J. - Tuesday, October 20th 2015 [ME NewsWire]
(BUSINESS WIRE)-- Adare Pharmaceuticals, Inc. announced today that James (Jim) Jogerst has joined the Company as Vice President, Corporate Development. He will be based at the Company’s headquarters in Princeton, NJ.
“We are delighted to have Jim join the Adare team. His extensive global experience in the areas of corporate development and M&A within the pharmaceutical and medical device industries will be key to our organization, as we implement our growth plans and strategy,” said John Fraher, President and CEO of Adare Pharmaceuticals.
Mr. Jogerst will be responsible for the global Corporate Development function and for the identification, evaluation and execution of new strategic business opportunities, including corporate and asset acquisitions, alliances and partnerships. He will also be involved in all aspects of the corporate development process with an intent to grow Adare as an innovative pharmaceutical company.
Mr. Jogerst brings 20 years of business development, licensing, M&A and corporate development experience in pharmaceuticals, medical device and diagnostics as well as in investment banking. He joins Adare from Alcon, a Novartis company, where he was Vice President, Head of Business Development, Licensing and M&A. In this role, Mr. Jogerst led a broad set of company and product acquisitions, licensing and investments. Previously, he held a number of senior roles in investment banking and strategic consulting for ISI Partners, Hoak Breedlove Wesneski & Company and Arthur Andersen.
After earning a BA in Economics and Political Science from the University of North Texas, Mr. Jogerst went on to achieve his MBA in Finance and International Business from Pepperdine University.
Adare Pharmaceuticals, Inc. was formerly known as Aptalis Pharmaceutical Technologies.
About Adare Pharmaceuticals
Adare Pharmaceuticals provides enhanced medicines, creating new possibilities for improved patient health. For decades, the company has solved complex formulation, manufacturing and commercialization challenges, resulting in transformational medicines that deliver value to all its stakeholders. Adare Pharmaceuticals has a global presence with R&D, manufacturing and commercial operations in the Unites States, Europe and Canada. For more information, visit www.adarepharma.com.
Cohn & Wolfe
Meghan Flanagan, 212-798-9863